Nick Robbins-Cherry
Chief Financial Officer @Epsilogen Ltd
Signup · Get unlimited contacts
WORK HISTORY
Chief Financial Officer @Epsilogen Ltd
London, GB
Clinical stage cancer immunotherapy company with operations in London and Boston. Epsilogen is the world\'s leading pan-isotype cancer antibody company, developing both IgE and IgA based therapeutics. The Company\'s lead asset, MOv18 IgE is in a phase Ib trial in platinum resistant ovarian cancer with a second asset in the clinic in 2026- Acquired Boston based TigaTx, Inc. in March 2025, adding IgA antibodies to the portfolio- £12.5m Series B expansion completed in September 2024, in a very difficult financing market.
EDUCATION
University of Bath
BSc, Pharmacology
Henley Business School
MBA
SKILLS
ABOUT NICK ROBBINS-CHERRY
Big 4 trained Chartered Accountant and MBA with extensive fund-raising, public markets, PE and VC experience gained through finance and commercial roles in international pharmaceuticals, technology services, software and telecoms businesses.Currently, Chief Financial Officer of a UK/US clinical stage cancer immunotherapy business, Epsilogen Limited, recently completing the acquisition of US based TigaTx, Inc. Formerly, I was CFO of Midatech Pharma PLC (now Biodexa Pharmaceuticals), a listed pharmaceutical business with R&D facilities in the UK and previously with operations in the US and Spain. Steered Midatech through its IPO on AIM, a dual listing on NASDAQ and subsequent fundraises.Strategic and commercial leader with the skills and experience to work effectively across all levels of an organisation. In a former role as CFO of Biodexa PLC I steered that business through IPOs on AIM and NASDAQ and subsequent fundraising rounds. Successful negotiator with excellent communication skills and an extensive track record in M&A.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.